8-K: Trevi Therapeutics Announces Second Quarter 2024 Financial Results and Provides Clinical Trial Updates

Trevi Therapeutics reported its Q2 2024 financial results and provided updates on its clinical trials for Haduvio, including expected topline data readouts and a sample size re-estimation milestone.

Summary

• Trevi Therapeutics announced its financial results for the second quarter of 2024, reporting a net loss of $12.4 million, compared to a net loss of $7.1 million in the same period in 2023.
• The company's research and development expenses increased to $10.0 million in Q2 2024, up from $5.8 million in Q2 2023, due to increased clinical trial activity.
• General and administrative expenses also increased to $3.3 million in Q2 2024 from $2.5 million in Q2 2023.
• Trevi ended the second quarter with $69.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.
• The Phase 2a RIVER trial for refractory chronic cough (RCC) is approximately 80% enrolled, with topline data expected in the fourth quarter of 2024.
• The Phase 2b CORAL trial for chronic cough in idiopathic pulmonary fibrosis (IPF) expects a sample size re-estimation in the fourth quarter of 2024, with topline results expected in the first half of 2025.
• The Human Abuse Potential (HAP) study is approximately 95% enrolled, with the last patient visit expected by the end of September and topline data expected in the fourth quarter of 2024.
• The Phase 1b TIDAL respiratory physiology study has initiated screening and will evaluate the effect of Haduvio on respiratory physiology in IPF patients.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and the company's cash runway, but the increased net loss and expenses temper the overall outlook.

Positives

• The company has a strong cash position of $69.5 million, providing a cash runway into 2026.
• Enrollment in the Phase 2a RIVER trial is progressing well, with 80% of patients enrolled.
• The company is advancing multiple clinical trials, including the Phase 2b CORAL trial, the HAP study, and the Phase 1b TIDAL study.
• The company has appointed a new Vice President of Clinical Development, Margaret Garin, MD, MSCR.

Negatives

• The company reported a net loss of $12.4 million for the second quarter of 2024, which is higher than the $7.1 million loss in the same period in 2023.
• Research and development expenses have increased significantly, indicating higher spending on clinical trials.
• General and administrative expenses have also increased, contributing to the higher net loss.

Risks

• The success of the clinical trials is uncertain, and positive data from one trial may not predict the results of later trials.
• Regulatory authorities' views on the clinical trial data and the development path for Haduvio are uncertain.
• The company's ability to fund future operations, including clinical trials, is subject to uncertainties.
• There are risks associated with estimating the company's cash runway, future expenses, and other financial results.

Future Outlook

The company expects topline data from the Phase 2a RIVER trial and the HAP study in the fourth quarter of 2024, and a sample size re-estimation for the Phase 2b CORAL trial in the fourth quarter of 2024, with topline results expected in the first half of 2025, assuming no adjustments are made to the sample size. The company's cash runway is expected to extend into 2026.

Management Comments

• Jennifer Good, President and CEO of Trevi Therapeutics, stated that recruitment in their clinical trials was strong during the quarter.
• She also mentioned that they look forward to the topline data readout for the Phase 2a RIVER trial later this year.
• She highlighted the significant unmet need for new therapies to help IPF and RCC patients.

Industry Context

Trevi Therapeutics is focused on developing treatments for chronic cough in IPF and RCC, areas with significant unmet medical needs and no approved therapies. This positions them to potentially capture a significant market share if their clinical trials are successful. The company's focus on a dual-mechanism drug, Haduvio, is also notable in the context of the industry's search for more effective treatments for these conditions.

Comparison to Industry Standards

• Trevi's increased R&D spending is typical for a clinical-stage biopharmaceutical company advancing multiple trials.
• The company's cash runway into 2026 is a positive sign, as many similar companies face funding challenges.
• The timelines for topline data readouts are consistent with industry standards for Phase 2 trials.
• Bellus Health, where the new VP of Clinical Development previously worked, is a competitor in the chronic cough space, making her experience relevant.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the progress in clinical trials and the cash runway.
• Employees may be impacted by the increased personnel expenses and the company's overall financial performance.
• Patients with chronic cough in IPF and RCC may benefit from the potential development of Haduvio.
• Creditors may be reassured by the company's cash position and expected runway.

Next Steps

• The company will continue enrollment in the Phase 2a RIVER and Phase 2b CORAL trials.
• The company will conduct a sample size re-estimation for the Phase 2b CORAL trial in the fourth quarter of 2024.
• The company will complete the Human Abuse Potential (HAP) study and report topline data in the fourth quarter of 2024.
• The company will continue the Phase 1b TIDAL respiratory physiology study.
• The company plans to participate in several upcoming industry conferences.

Key Dates

Keywords

Trevi Therapeutics, Haduvio, chronic cough, idiopathic pulmonary fibrosis, refractory chronic cough, clinical trials, RIVER trial, CORAL trial, HAP study, TIDAL study, financial results, biopharmaceutical